Cardiff Oncology, Inc. CRDF
Verdict: Sell. Fair value $9.68 against a price of $2.84 on 6 Jan 2026, 241% above the price.
In plain words
The case for: Industry tailwinds with growing market.
The case against: High industry disruption risk. Intense competitive pressure could compress margins. The company has zero revenue and is experiencing accelerating net losses (from -$0.02B in 2020 to....
Main risks
- No Revenue & Accelerating Cash Burn: The company is pre-commercial with zero revenue and widening net losses, from -$0.02B in 2020 to -$0.05B in 2024. Survival is entirely dependent on successful clinical trials and continued access to capital markets.
- Binary Outcome Risk: As a clinical-stage biotech, its value is almost entirely dependent on the success of its lead drug candidate, Onvansertib. A negative trial result would be catastrophic for equity value.
- Negative Returns on Incremental Capital: The calculated 3-year ROIIC is -7.7%, indicating that for every dollar of new capital invested over the past three years, operating losses have worsened. This highlights the high cost and uncertainty of the R&D phase.
- The company has zero revenue and is experiencing accelerating net losses (from -$0.02B in 2020 to...
- As a clinical-stage biotech with no revenue-generating products, the company's operations and...
- High industry disruption risk